Trial Profile
A Multicentre Extension Study to Evaluate the Long-Term Safety and Durability of the Therapeutic Effect of LUM001 Also Known as Maralixibat (MRX), an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Jun 2022
Price :
$35
*
At a glance
- Drugs Maralixibat (Primary)
- Indications Alagille syndrome; Cholestasis; Liver disorders
- Focus Therapeutic Use
- Acronyms IMAGINE
- Sponsors Lumena Pharmaceuticals; Mirum Pharmaceuticals; Shire; Takeda
- 24 Jun 2022 According to a Mirum Pharmaceuticals media release, data from this study presented at the 54th Annual European Society for Paediatric Gastroenterology, Hepatology, and Nutrition Annual Meeting (ESPGHAN)
- 13 Jun 2022 According to a Mirum Pharmaceuticals media release, data from this study will be presented at the 54th Annual European Society for Paediatric Gastroenterology, Hepatology, and Nutrition Annual Meeting (ESPGHAN)
- 03 Jun 2021 Results published in the Mirum Pharmaceuticals Media Release.